Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 34 citing articles:

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
Bin‐Yan Zhong, Zhi‐Cheng Jin, Jian-Jia Chen, et al.
Journal of Clinical and Translational Hepatology (2022) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 53
Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study
Xukun Wu, Lanfang Yang, Yufeng Chen, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102367-102367
Open Access | Times Cited: 25
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities
Ming‐Da Wang, Xuejun Xu, Ke‐Chun Wang, et al.
Cancer Science (2024) Vol. 115, Iss. 7, pp. 2159-2169
Open Access | Times Cited: 12
Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
Yonglin Hua, Zhixian Sun, Yuxin Xiao, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 7, pp. e008953-e008953
Open Access | Times Cited: 12
The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
Qiao Ke, Fuli Xin, Huipeng Fang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 37
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study
Jiayi Wu, Zhibo Zhang, Jianyin Zhou, et al.
Liver Cancer (2022) Vol. 12, Iss. 3, pp. 229-237
Open Access | Times Cited: 31
Recent Progress in Advanced Hydrogel‐Based Embolic Agents: From Rational Design Strategies to Improved Endovascular Embolization
Xiaohong Li, Muhammad Wajid Ullah, Basen Li, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 17
Closed Access | Times Cited: 21
Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors
Xingzhi Li, Jie Chen, Xiaobo Wang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 15
Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
Jintao Huang, Bin‐Yan Zhong, Nan Jiang, et al.
Journal of Hepatocellular Carcinoma (2022) Vol. Volume 9, pp. 1217-1228
Open Access | Times Cited: 19
Safety and Survival Outcomes of Liver Resection following Triple Combination Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma
Yin Long, Jue Huang, Jianguo Liao, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5878-5878
Open Access | Times Cited: 12
PD1+ Treg cell remodeling promotes immune homeostasis within peripheral blood and tumor microenvironment after microparticles-transarterial chemoembolization in hepatocellular carcinoma
Zhizhong Ren, Yaqin Wang, Dandan Jiang, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 3
Open Access
Efficacy and safety of TACE combined with TKIs and PD-1 inhibitors in HCC patients with prior TIPS
Kai Xiong, Kuiyuan Huang, Yulong Liu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Therapeutic Response-Driven Discrepancies in Intratumoral Microbiome Composition of Hepatocellular Carcinoma Following Conversion Therapy
Lin Ma, Jiamei Xu, Fuhai Wang, et al.
Research Square (Research Square) (2025)
Closed Access
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
Liwei Sun, Xuelong Xu, Fanguang Meng, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
Shuqun Li, Junyi Wu, Jiayi Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Nanoparticle/Engineered Bacteria Based Triple-Strategy Delivery System for Enhanced Hepatocellular Carcinoma Cancer Therapy
Meiyang Yang, Weijun Chen, Dhanu Gupta, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 3827-3846
Open Access | Times Cited: 3
Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
Tong Liu, Guorui Meng, Shihui Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
An overview: Management of patients with advanced hepatocellular carcinoma
Jincheng Wang, Rui Wu, Jin-Yu Sun, et al.
BioScience Trends (2022) Vol. 16, Iss. 6, pp. 405-425
Open Access | Times Cited: 11
Perioperative safety, oncologic outcome, and risk factors of salvage liver resection for initially unresectable hepatocellular carcinoma converted by transarterial chemoembolization plus tyrosine kinase inhibitor and anti-PD-1 antibody: a retrospective multicenter study of 83 patients
Kongying Lin, Zhi-Wen Lin, Qing-Jing Chen, et al.
Hepatology International (2023) Vol. 17, Iss. 6, pp. 1477-1489
Closed Access | Times Cited: 6
Conversion surgery for initially unresectable hepatocellular carcinoma using lenvatinib combined with TACE plus PD-1 inhibitor: A real-world observational study
Xingzhi Li, Xiaobo Wang, Tao Bai, et al.
Digestive and Liver Disease (2023) Vol. 56, Iss. 6, pp. 1078-1086
Closed Access | Times Cited: 5
Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
Bingran Yu, Ning Zhang, Yun Feng, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 1735-1748
Open Access | Times Cited: 4
Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
Hao Li, Jiacheng Wang, Guokun Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Benjian Gao, Fengyi Yang, Dongning Zheng, et al.
Journal of Hepatocellular Carcinoma (2023) Vol. Volume 10, pp. 2265-2276
Open Access | Times Cited: 4
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody
Lei Wang, Jin-Kai Feng, Chong‐De Lu, et al.
The Oncologist (2024)
Open Access | Times Cited: 1
Combination therapy consisting of transarterial chemoembolization, lenvatinib, and programmed cell death protein 1 blockade for hepatocellular carcinoma with inferior vena cava tumor thrombus: a case series study and literature review
Yang-Kai Fu, Yinan Li, De-Yi Liu, et al.
Oncology Research and Treatment (2024) Vol. 47, Iss. 10, pp. 465-473
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top